skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Datamonitor Healthcare has identified the following key highlights from the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, which was held between 30 May and 3 June 2014:


  • Results from early-phase clinical trials of AstraZeneca’s AZD9291 and Clovis Oncology’s CO-1686 demonstrate strong efficacy of both drugs in relapsed/refractory non-small cell lung cancer (NSCLC) patients with T790M mutations.


  • Programmed death 1-targeted immunotherapies were a key highlight of ASCO 2014.


  • Imbruvica’s (ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results confirm its strong efficacy as a single agent for the treatment of chronic lymphocytic leukemia (CLL).


  • Phase II data demonstrate Amgen’s novel antibody therapy blinatumomab is highly effective as a treatment for Philadelphia chromosome (Ph)-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).


  • Results from the Phase II ROMULUS trial showed that when combined with Rituxan (rituximab; Roche), Roche’s investigational antibody-drug conjugates polatuzumab vedotin (PoV) and pinatuzumab vedotin (PiV) are clinically active and well tolerated in relapsed/refractory follicular lymphoma (FL) and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients.